Metastatic non-seminomatous testis tumors: morbidity of treatment

There were 28 patients with metastatic non-seminomatous testis tumors treated by a regimen of combined retroperitoneal lymphadenectomy and multiple drug chemotherapy. We have outlined the morbidity of this plan of management with a followup of 3 to 8 years. Survival for all patients with stage B disease is 100 per cent and with stage C disease it is 58 per cent (8 of 14 patients).